- Sweden
- /
- Life Sciences
- /
- OM:MAGLE
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Unsurprisingly, Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in the numbers.
View our latest analysis for Magle Chemoswed Holding
In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. Magle Chemoswed Holding expanded the number of shares on issue by 70% over the last year. Therefore, each share now receives a smaller portion of profit. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. You can see a chart of Magle Chemoswed Holding's EPS by clicking here.
A Look At The Impact Of Magle Chemoswed Holding's Dilution On Its Earnings Per Share (EPS)
As you can see above, Magle Chemoswed Holding has been growing its net income over the last few years, with an annualized gain of 531% over three years. But EPS was only up 378% per year, in the exact same period. And the 104% profit boost in the last year certainly seems impressive at first glance. On the other hand, earnings per share are only up 104% in that time. So you can see that the dilution has had a fairly significant impact on shareholders.
In the long term, earnings per share growth should beget share price growth. So Magle Chemoswed Holding shareholders will want to see that EPS figure continue to increase. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Magle Chemoswed Holding's Profit Performance
As we discussed above, Magle Chemoswed Holding's dilution over the last year has a major impact on its per-share earnings. For this reason, we think that Magle Chemoswed Holding's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Every company has risks, and we've spotted 2 warning signs for Magle Chemoswed Holding (of which 1 makes us a bit uncomfortable!) you should know about.
Today we've zoomed in on a single data point to better understand the nature of Magle Chemoswed Holding's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:MAGLE
Magle Chemoswed Holding
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
Solid track record and fair value.